SAB Biotherapeutics, Inc.
SABS
NASDAQ·Healthcare·Biotechnology·Mkt cap $338.5M
$3.72
▲ 0.00%
P/E
-5.90
Mkt Cap
$338.5M
52-Wk Range
$1.85–$5.15
52-Week Range
$1.85 - $5.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 77.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+10.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SABS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 6, 2026
Reported EPS of -$0.28 vs -$0.28 consensus (+1.1% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.1%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Jun 24, 2026
vs Industry
How SABS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.